Acrivon Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ACRV Nasdaq 2834 www.acrivon.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Acrivon Therapeutics, Inc.

Here's Why Acrivon Therapeutics, Inc. (ACRV) Is a Great 'Buy the Bottom' Stock Now - May 5th, 2025 1:55 pm
Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025 - Apr 25th, 2025 12:00 pm
April 2025's Standout Penny Stocks - Apr 22nd, 2025 6:05 pm
Down -70.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Acrivon Therapeutics, Inc. (ACRV) - Apr 14th, 2025 1:35 pm
Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer - Apr 7th, 2025 8:05 pm
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's What You Should Know - Mar 28th, 2025 4:00 pm
Here's Why Acrivon Therapeutics, Inc. (ACRV) is Poised for a Turnaround After Losing -52.81% in 4 Weeks - Mar 28th, 2025 1:35 pm
Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results - Mar 27th, 2025 9:44 pm
Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates - Mar 19th, 2025 12:00 pm
We're Hopeful That Acrivon Therapeutics (NASDAQ:ACRV) Will Use Its Cash Wisely - Feb 12th, 2025 1:47 pm
Acrivon Therapeutics announces FDA granted BDD for ACR-368 - Feb 6th, 2025 1:16 pm
FDA grants breakthrough designation for Acrivon’s endometrial cancer assay - Feb 6th, 2025 9:54 am
Acrivon Therapeutics (ACRV): AI-Powered Precision Oncology Gets FDA Breakthrough Status - Feb 5th, 2025 8:45 pm
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer - Feb 5th, 2025 1:00 pm
Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights - Nov 13th, 2024 12:00 pm
Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium - Oct 17th, 2024 12:00 pm
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Oct 16th, 2024 8:00 pm
Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline - Oct 12th, 2024 12:28 pm
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity - Oct 11th, 2024 12:00 pm
Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis - Sep 14th, 2024 7:10 am